Objective: To evaluate tocilizumab (TCZ) efficacy in patients with refractory Behçet disease (BD). Methods: This is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation. Results: Ninety percent of patients with BD were refractory or intolerant to anti-tumor necrosis factor (anti-TNF) agents. Overall, TCZ was effective in 25 (83%) patients with BD of whom 18 (60%) and 7 (23%) were complete and partial responders, respectively. The complete response was 67%, 60%, and 42% in patients with uveitis (18/30), neurological manifestations (5/30), and mucocutaneous and/or articular (7/30) manifestations, respectively. TCZ had a significant steroid-sparing effect allowing patients to decrease their median daily prednisone dose from 20 (IQR 10-40) mg/day to 9 (IQR 5-13) mg at 6 months (P < 0.001). The number of patients with BD needing concomitant disease-modifying antirheumatic drug therapy fell from 7 (23%) to 4 (13%) at 6 months. Mild to moderate side effects were observed in 6 (20%) patients, and 3 (10%) presented with serious adverse events (pneumonia, intestinal perforation, and septicemia) requiring therapy discontinuation in 2 cases. Conclusion: TCZ seems to be an effective alternative to anti-TNF agents in treating BD-related uveitis and neurological manifestations.

Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients / Khitri, Mohamed-Yacine; Bartoli, Alessandra; Maalouf, Georgina; Deroux, Alban; Salvarani, Carlo; Emmi, Giacomo; Karadag, Omer; Espinosa, Gerard; Leclercq, Mathilde; Simonini, Gabriele; Vautier, Mathieu; Cacoub, Patrice; Saadoun, David. - In: THE JOURNAL OF RHEUMATOLOGY. - ISSN 0315-162X. - ELETTRONICO. - (2023), pp. jrheum.221106-jrheum.221106. [10.3899/jrheum.221106]

Tocilizumab in Behçet Disease: A Multicenter Study of 30 Patients

Emmi, Giacomo;Simonini, Gabriele;
2023

Abstract

Objective: To evaluate tocilizumab (TCZ) efficacy in patients with refractory Behçet disease (BD). Methods: This is a multicenter study of 30 patients fulfilling the international criteria for BD and treated with TCZ at different European referral centers. The clinical response was evaluated at 6 months from TCZ initiation. Results: Ninety percent of patients with BD were refractory or intolerant to anti-tumor necrosis factor (anti-TNF) agents. Overall, TCZ was effective in 25 (83%) patients with BD of whom 18 (60%) and 7 (23%) were complete and partial responders, respectively. The complete response was 67%, 60%, and 42% in patients with uveitis (18/30), neurological manifestations (5/30), and mucocutaneous and/or articular (7/30) manifestations, respectively. TCZ had a significant steroid-sparing effect allowing patients to decrease their median daily prednisone dose from 20 (IQR 10-40) mg/day to 9 (IQR 5-13) mg at 6 months (P < 0.001). The number of patients with BD needing concomitant disease-modifying antirheumatic drug therapy fell from 7 (23%) to 4 (13%) at 6 months. Mild to moderate side effects were observed in 6 (20%) patients, and 3 (10%) presented with serious adverse events (pneumonia, intestinal perforation, and septicemia) requiring therapy discontinuation in 2 cases. Conclusion: TCZ seems to be an effective alternative to anti-TNF agents in treating BD-related uveitis and neurological manifestations.
2023
jrheum.221106
jrheum.221106
Khitri, Mohamed-Yacine; Bartoli, Alessandra; Maalouf, Georgina; Deroux, Alban; Salvarani, Carlo; Emmi, Giacomo; Karadag, Omer; Espinosa, Gerard; Lecle...espandi
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificatore per citare o creare un link a questa risorsa: https://hdl.handle.net/2158/1308376
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 9
  • ???jsp.display-item.citation.isi??? 7
social impact